Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
McKinsey
AstraZeneca
McKesson
Boehringer Ingelheim
Julphar
Moodys
Colorcon

Generated: November 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,741,963

« Back to Dashboard

Title:S1P receptor modulators for treating multiple sclerosis
Abstract: The present invention relates to the use of the S1P receptor modulator 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, administered at a daily dosage of 0.5 mg, for inhibiting or treating neo-angiogenesis associated with multiple sclerosis.
Inventor(s): Hiestand; Peter C. (Allschwil, CH), Schnell; Christian (Hesingue, FR)
Assignee: Novartis AG (Basel, CH)
Filing Date:May 31, 2011
Application Number:13/149,468
Claims:1. A method for inhibiting or treating neo-angiogenesis associated with multiple sclerosis in a subject in need thereof, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.

2. A method according to claim 1, wherein said multiple sclerosis is primary progressive multiple sclerosis.

3. A method according to claim 1 wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered.

4. A method according to claim 3, wherein said multiple sclerosis is primary-progressive multiple sclerosis.

5. A method according to claim 2, wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered.

6. A method according to claim 1, wherein said multiple sclerosis is relapsing-remitting multiple sclerosis.

7. A method for reducing or alleviating relapses in primary progressive multiple sclerosis in a subject in need thereof, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.

8. A method according to claim 7, wherein 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride is administered.

9. A method for slowing progression of multiple sclerosis in a subject in the relapsing-remitting phase of primary progressive multiple sclerosis, comprising administering to said subject 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in free form or in a pharmaceutically acceptable salt form, at a daily dosage of 0.5 mg, absent an immediately preceding loading dose regimen.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Fuji
US Department of Justice
Chubb
US Army
Accenture
AstraZeneca
UBS
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.